The Effect of Medical Lowering of Intraocular Pressure on Peripapillary and Macular Blood Flow as Measured by Optical Coherence Tomography Angiography in Treatment-naive Eyes.
Liu Chang, Umapathi Ruthra M, Atalay Eray, Schmetterer Leopold, Husain Rahat, Boey Pui Yi, Aung Tin, Nongpiur Monisha E
AI Summary
Latanoprost-induced IOP reduction in treatment-naive eyes significantly correlated with increased optic nerve head and peripapillary capillary vessel density, suggesting improved ocular microperfusion as a glaucoma treatment mechanism.
Abstract
Prcis: Reduction of intraocular pressure (IOP) by latanoprost in treatment-naive eyes is significantly correlated to an increase in vessel density (VD) at the optic nerve head (ONH).
Purpose
To evaluate the effect of topical latanoprost on ocular microvasculature using optical coherence tomography angiography (OCTA).
Patients and methods: In this prospective case-control study, 26 eyes from 18 treatment-naive subjects in whom prostaglandin analogue (PGA) latanoprost 0.005% was initiated were included as cases. In 10 out of the 18 subjects, medication was initiated in only 1 eye; their contralateral untreated eyes were used as controls. OCTA (AngioVue, Optovue Inc., Fremont, CA) was performed at baseline and ≥3 weeks after commencing treatment. Main outcome measures were change in flow area and VD at the ONH, radial peripapillary capillaries (RPC), and macula. Comparison between the 2 visits was performed using a linear mixed model adjusted for intereye correlation and mean ocular perfusion pressure.
Results
IOP decreased by 26.1%±11.3% (P<0.001) in the cases and 0.18%±12.2% (P=0.63) in controls. Significant correlations between change in IOP and change in ONH VD (correlation coefficient [r]=-0.42, P=0.04), and between change in IOP and change in RPC VD (r=-0.48, P=0.02) were observed in the cases, whereas none were observed in the controls. When multiple testing was considered, no significant changes in flow area and VD were observed in cases and controls.
Conclusions
The reduction of IOP by a PGA in treatment-naive eyes was significantly correlated to the increase in ONH VD and RPC VD. This may indicate a mechanism by which IOP reduction modulates the risk of glaucoma progression by improving ocular microperfusion.
MeSH Terms
Shields Classification
Key Concepts4
In a prospective case-control study of 26 eyes from 18 treatment-naive subjects, latanoprost 0.005% significantly decreased intraocular pressure (IOP) by 26.1% 11.3% (P<0.001) in cases.
In a prospective case-control study of 26 eyes from 18 treatment-naive subjects, a significant correlation was observed between change in IOP and change in optic nerve head (ONH) vessel density (correlation coefficient [r]=-0.42, P=0.04) in cases treated with latanoprost 0.005%.
In a prospective case-control study of 26 eyes from 18 treatment-naive subjects, a significant correlation was observed between change in IOP and change in radial peripapillary capillaries (RPC) vessel density (correlation coefficient [r]=-0.48, P=0.02) in cases treated with latanoprost 0.005%.
In a prospective case-control study of 26 eyes from 18 treatment-naive subjects, the reduction of intraocular pressure (IOP) by a prostaglandin analogue (latanoprost 0.005%) in treatment-naive eyes was significantly correlated to the increase in optic nerve head (ONH) vessel density and radial peripapillary capillaries (RPC) vessel density, suggesting a mechanism by which IOP reduction modulates the risk of glaucoma progression by improving ocular microperfusion.
Related Articles5
Optic disk topography after medical treatment to reduce intraocular pressure.
Clinical TrialThe Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma.
Clinical TrialThe acute morphologic changes that occur at the optic nerve head induced by medical reduction of intraocular pressure.
Clinical TrialEffects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow.
Clinical TrialRetinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.
Cohort StudyIs this article assigned to the wrong chapter(s)? Let us know.